Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Lockhart, A Craig, Bauer, Todd M., Aggarwal, Charu, Lee, Carrie B., Harvey, R Donald, Cohen, Roger B., Sedarati, Farhad, Nip, Tsz Keung, Faessel, Hélène, Dash, Ajeeta B., Dezube, Bruce J., Faller, Douglas V., Dowlati, Afshin
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2018
Témata:
Phase I Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510847/
https://ncbi.nlm.nih.gov/pubmed/29781056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0610-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky